Cellectis/ISU ink TALENS deal
French genomics company Cellectis (Paris) has signed two exclusive licensing agreements with the US Iowa State University (Ames) giving Cellectis worldwide rights to use inventions related to transcription activator-like effector-nucleases (TALENs) and monomeric TALENs. The licences cover all uses of the TAL technologies in any field. TALENs are sequence-specific DNA nucleases that can be custom engineered to target and modify any gene of interest, in any species. The technology has broad applications in genome engineering including fundamental genetic research, crop improvement, and treatment of human genetic diseases.